COX-2 Gene SNPs in T-Cell Differentiation
This study aims to observe if specific variations in the COX-2 gene, namely 765>C and 8473T>C, are associated with changes in the differentiation of certain T-cells (Th2, Th9, and Th17) in your body.
Data Collection
Collected at a single point in time - Cross-sectionalBronchial Diseases+6
+ Hypersensitivity
+ Hypersensitivity, Immediate
Cohort
Tracking disease incidence in order to identify risk factors and understand disease progression over time.Summary
Study start date: May 2, 2013
Actual date on which the first participant was enrolled.This is a cross-sectional, controlled study designed to investigate the association of single nucleotide polymorphisms (SNPs) in the cyclooxygenase-2 (COX2) gene, also called prostaglandin endoperoxidase synthase 2 (PTGS2), on T-cell differentiation and function. Specifically, the impact of the promoter-region SNP 765G>C (rs20417) and the 3 untranslated region (UTR) SNP 8473T>C (rs5275) on T helper cell (Th) 2, Th9, and Th17 differentiation and function will be examined. Non-Hispanic, White or Black/African American, non-pregnant adults, aged 18-65 years, who are wild type (WT), with respect to both the 765G>C and 8473T>C SNPs, WT with respect to 765G>C and homozygous for 8473T>C, and homozygous for both 765G>C and 8473T>C will be recruited into a total of three genotype groups. Potential participants will be identified from the Environmental Polymorphisms Registry, contacted by recruitment letter and pre-screened for eligibility. Pre-screened individuals will provide verbal consent to withhold certadata analysis, a urine collection cup, and pre-visit instructions. Participants will attend a single study visit that will take place at the National Institute of Environmental Health Sciences (NIEHS) Clinical Research Unit (CRU). During this visit, written informed consent will be obtained, and there will be a final screening and eligibility determination, medical history review, vital signs, physical examination and blood and urine samples will be collected. From peripheral blood, lymphocyte subsets, prostaglandin levels, and cytokine levels will be determined; stable prostaglandin metabolites, creatinine, total protein and albumin will be measured in urine. Lymphocytes will be isolated from peripheral blood for ex vivo analyses. Demographic characteristics (i.e., age) will be compared between the groups, and when possible, recruitment will be targeted to achieve an approximate match of race and gender across the groups. The primary objective of the study is to determine whether the 765G>C or 8473T>C SNPs exhibit altered Th2, Th9 and Th17 cell differentiation by examining lymphocyte subsets in vivo. The study will also examine the impact of these two SNPs on circulating Th2/Th9/Th17 cytokine levels and prostaglandins in vivo, on differentiation of naive CD4+T-cells to Th cell subsets in vitro, and on lymphocyte production of cytokines and prostaglandins in vitro.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.117 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Cohort
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 18 to 150 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
* INCLUSION CRITERIA: * Participant of the Environmental Polymorphisms Registry and current contact information available * Genotype information available for relevant 765G\>C and 8473T\>C COX2 polymorphisms, which indicates: * Individuals who are WT with respect to both 765G\>C and 8473T\>C (N=31) * Individuals who are WT with respect to 765G\>C and homozygous for 8473T\>C (N=31) * Individuals who are homozygous for both 765G\>C and 8473T\>C (N=31) * Age 18- 65 years * Race self-identified as White or Black and Non-Hispanic ethnicity * Willing and able to provide informed consent * Able to comply with all protocol procedures EXCLUSION CRITERIA: * History of infection within the preceding 1 week or an oral temperature \>38 degrees C * Current daily or chronic use of corticosteroids (systemic, inhaled and topical). * Any current conditions known to impact peripheral white blood cell count (e.g., leukemia, lymphopenia, AIDS, other immunodeficiency disorders) * Current daily or chronic use of systemic immunosuppressants. * Current pregnancy or lactation * Unwilling or unable to: * Fast (including alcohol and caffeine-containing products) and discontinue tobacco use for 12 hours prior to the study visit * Withhold all prescribed and over-the-counter medications and supplements the morning of the study visit, until after the visit is completed * Refrain from taking the following medications and supplements for 7 days prior to the study visit: * NSAIDs * Corticosteroids (nasal, inhaled, topical or systemic) * Fish oil and niacin supplements * For blood draws that exceed 200ml, a hematocrit of \<34% for women or \<36% for men, or \>56% for either gender. * For blood draws exceeding 200ml, blood or plasma donation in the last 8 weeks
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Study Objectives
Primary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
NIEHS Clinical Research Unit (CRU)
Research Triangle Park, United StatesOpen NIEHS Clinical Research Unit (CRU) in Google Maps